Larimar Therapeutics (ZA71) Stock Statistics & Valuation Metrics
Total Valuation
Larimar Therapeutics has a market cap or net worth of EUR 229.75M. The enterprise value is EUR 167.06M.
- Market Cap
- EUR 229.75M
- Enterprise Value
- EUR 167.06M
Share Statistics
Larimar Therapeutics has 103,882,935 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 103,882,935
- Owned by Insiders
- 36.03%
- Owned by Institutions
- 16.64%
Financial Efficiency
Larimar Therapeutics’s return on equity (ROE) is -2.12 and return on invested capital (ROIC) is -209.97%.
- Return on Equity (ROE)
- -2.12
- Return on Assets (ROA)
- -1.14
- Return on Invested Capital (ROIC)
- -209.97%
- Return on Capital Employed (ROCE)
- -2.13
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.33M
- Employee Count
- 71
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Larimar Therapeutics is -1.24. Larimar Therapeutics’s PEG ratio is 0.04.
- PE Ratio
- -1.24
- PS Ratio
- 0.00
- PB Ratio
- 2.01
- Price to FCF
- -1.64
- Price to Operating Cash Flow
- -1.65
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, Larimar Therapeutics had revenue of 0 and earned -165.67M in profits. Earnings per share was -2.27.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -172.50M
- Pretax Income
- -165.67M
- Net Income
- -165.67M
- EBITDA
- -165.32M
- Earnings Per Share (EPS)
- -2.27
Cash Flow
In the last 12 months, operating cash flow was -155.92M and capital expenditures -153,000, giving a free cash flow of -156.08M billion.
- Operating Cash Flow
- -155.92M
- Free Cash Flow
- -156.08M
- Free Cash Flow per Share
- -1.50
Dividends & Yields
Larimar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -60.83%
- Earnings Yield
- -67.27%
Stock Price Statistics
- Beta
- 0.81
- 52-Week Price Change
- -37.90%
- 50-Day Moving Average
- 2.79
- 200-Day Moving Average
- 3.26
- Relative Strength Index (RSI)
- 47.88
- Average Volume (3m)
- 1,707
Important Dates
Larimar Therapeutics upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Larimar Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 5.21%
- Current Ratio
- 2.19
- Quick Ratio
- 2.19
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.49
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Larimar Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Larimar Therapeutics EV to EBITDA ratio is -0.98, with an EV/FCF ratio of -1.08.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.98
- EV to Free Cash Flow
- -1.08
- EV to Operating Cash Flow
- -1.08
Balance Sheet
Larimar Therapeutics has EUR 156.27M in cash and marketable securities with EUR 4.96M in debt, giving a net cash position of EUR 151.31M billion.
- Cash & Marketable Securities
- EUR 156.27M
- Total Debt
- EUR 4.96M
- Net Cash
- EUR 151.31M
- Net Cash Per Share
- EUR 1.46
- Tangible Book Value Per Share
- EUR 1.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Larimar Therapeutics is EUR 14.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 14.58
- Price Target Upside
- 544.95% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -18.05%
Scores
- Smart Score
- 3
- AI Score
- ―
